Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A

ClinicalTrials.gov ID: NCT01480180

Public ClinicalTrials.gov record NCT01480180. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-national Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Patients With Haemophilia A

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is conducted globally. The aim of the trial is to evaluate the safety and efficacy, including pharmacokinetics (the exposure of the trial drug in the body) of NNC 0129-0000-1003 (N8-GP) in subjects with Haemophilia A.

Study identification

NCT ID
NCT01480180
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
186 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 29, 2012
Primary completion
Dec 9, 2018
Completion
Dec 9, 2018
Last update posted
Nov 22, 2020

2012 – 2018

United States locations

U.S. sites
31
U.S. states
22
U.S. cities
29
Facility City State ZIP Site status
Novo Nordisk Investigational Site Phoenix Arizona 85016
Novo Nordisk Investigational Site Long Beach California 90806
Novo Nordisk Investigational Site Sacramento California 95817
Novo Nordisk Investigational Site Torrance California 90502-2004
Novo Nordisk Investigational Site Washington D.C. District of Columbia 20007
Novo Nordisk Investigational Site Washington D.C. District of Columbia 20010-2978
Novo Nordisk Investigational Site Orlando Florida 32827
Novo Nordisk Investigational Site Tampa Florida 33607
Novo Nordisk Investigational Site Augusta Georgia 30912
Novo Nordisk Investigational Site Boise Idaho 83712
Novo Nordisk Investigational Site Iowa City Iowa 52242
Novo Nordisk Investigational Site New Orleans Louisiana 70118-5720
Novo Nordisk Investigational Site Baltimore Maryland 21205
Novo Nordisk Investigational Site Boston Massachusetts 02115
Novo Nordisk Investigational Site Detroit Michigan 48201
Novo Nordisk Investigational Site East Lansing Michigan 48823
Novo Nordisk Investigational Site Minneapolis Minnesota 55404
Novo Nordisk Investigational Site Omaha Nebraska 68198-5456
Novo Nordisk Investigational Site New Brunswick New Jersey 08901
Novo Nordisk Investigational Site Newark New Jersey 07102
Novo Nordisk Investigational Site Cincinnati Ohio 452289
Novo Nordisk Investigational Site Dayton Ohio 45404
Novo Nordisk Investigational Site Portland Oregon 97239
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19104
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19134
Novo Nordisk Investigational Site Charleston South Carolina 29425
Novo Nordisk Investigational Site Nashville Tennessee 37232-9830
Novo Nordisk Investigational Site Houston Texas 77030
Novo Nordisk Investigational Site Charlottesville Virginia 22908
Novo Nordisk Investigational Site Norfolk Virginia 23507
Novo Nordisk Investigational Site Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01480180, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 22, 2020 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01480180 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →